HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute septic shock during pegylated-interferon and ribavirin therapy in a patient with chronic hepatitis C who underwent aortic graft replacement.

Abstract
We report an autopsied case of a 59-year-old woman with acute septic shock from methicillin-resistant Staphylococcus aureus (MRSA) infection during combination therapy with pegylated-interferon-α-2b (PEG-IFNα-2b) and ribavirin. She underwent aortic graft replacement for the treatment of a dissecting aneurysm. We observed her latent infection closely for over a year following the operation. The clinical and laboratory examinations did not show any sign of infection. She then underwent PEG-IFNα-2b/ribavirin combination therapy. In her 17th week of therapy, she suddenly complained of high fever followed by a markedly rapid progression of sepsis and disseminated intravascular coagulation. She died of acute septic shock from MRSA infection on her fourth hospital day. Autopsy revealed abscess formation in the mediastinum around the artificial vessel graft. There was no obvious verruca on the internal surface of the replaced graft. Microscopic examination revealed numerous cocci along the thread in the suture of the graft. This clinical experience shows that combination therapy with PEG-IFNα-2b/ribavirin for the treatment of chronic hepatitis C should be given careful consideration when administered to patients who have undergone major vessel surgery, such as aortic graft replacement. Once the treatment has been started, infection should be monitored with particular care and frequent medical examinations.
AuthorsYoshinao Kobayashi, Kohta Nishihama, Hidehiro Miyachi, Hideaki Tanaka, Norihiko Yamamoto, Mohoh Iwasa, Toshio Fukutome, Taizo Shiraishi, Yoshiyuki Takei
JournalClinical journal of gastroenterology (Clin J Gastroenterol) Vol. 4 Issue 3 Pg. 179-183 (Jun 2011) ISSN: 1865-7257 [Print] Japan
PMID26189351 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: